FARN – Faron Pharmaceuticals Oy
Faron Pharmaceuticals (LSE:FARN), the Finnish clinical-stage immuno-oncology company dual-listed on London's AIM and Nasdaq First North Growth Market in Helsinki, has given investors their first look at survival outcomes from its lead programme in a hard-to-treat blood cancer. On 27 July 2026 the company reported early overall survival (OS) data from treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS) patients treated with bexmarilimab alongside the chemotherapy azacitidine in the Phase 1/2 BEXMAB study.
The readout matters because survival, rather than response alone, is the measure regulators and clinicians ultimately weigh in HR-MDS, an aggressive bone-marrow malignancy where treatment options are limited and prognosis poor. After a run of encouraging response data, this is the first indication that those responses may be translating into patients living longer, and it arrives as Faron prepares a registrational trial that management has framed as its final study before a potential regulatory filing.
Company background
Faron (LSE:FARN) is a pre-revenue biotechnology business built around a single scientific idea: reprogramming the immune system by targeting myeloid cells. Its lead asset, bexmarilimab, is a humanised antibody directed at Clever-1, a receptor found on immunosuppressive macrophages. By blocking Clever-1, the drug is designed to switch macrophages from a tumour-protecting (M2) state to an immune-activating (M1) state, in theory restoring the body's ability to attack cancer.
In recent years the company has concentrated its resources on haematological malignancies, with HR-MDS as the flagship indication. As a company with no marketed products and no recurring revenue, Faron funds itself through equity, convertible debt and partnering income, which makes clinical progress and cash management two sides of the same story.
The survival readout
The 27 July announcement covered 21 treatment-naive HR-MDS patients, a group described as elderly and high-risk, of whom roughly 48% carried TP53 mutations, one of the most adverse genetic markers in the disease. At a median follow-up of 14.9 months, the company reported that median OS had not yet been reached in the TP53 wild-type and monoallelic TP53-mutated subgroups.
In the biallelic TP53-mutated group, historically the most treatment-resistant, median OS was 8.8 months, which Faron characterised as broadly consistent with historically poor outcomes for that population. On our reading, the significance lies less in the biallelic figure and more in the fact that the wild-type and monoallelic subgroups had not reached median survival at nearly 15 months, which management presents as an early, encouraging signal rather than a definitive result.
Response data behind the signal
The survival update built on efficacy data Faron presented at the European Hematology Association (EHA) congress on 15 June 2026. There the company reported an overall response rate of 85% and a complete remission (CR) rate of 45%, with a median CR duration of 16.1 months and full bone-marrow blast clearance in 60% of patients.
Faron also released translational evidence intended to explain the clinical picture, describing recovery of healthy progenitor cells, activated cytotoxic CD8+ T-cell responses and a reduction in exhausted T-cell populations. Chief Medical Officer Dr Petri Bono said the results support the potential of bexmarilimab in both TP53 wild-type and mutated HR-MDS, while the company stressed that the safety profile remained stable and well tolerated.
Financial position
The clinical momentum has been shadowed by a tight balance sheet. Directors had warned that cash would support operations only into the second quarter of 2026, after drawing a EUR 9.25 million convertible bond tranche in November 2025 to extend the runway.
That gap was addressed in April 2026, when Faron completed a rights issue raising gross proceeds of approximately EUR 40.1 million, equivalent to net proceeds of around EUR 32.8 million after costs. The offering issued 80 million new shares, lifting the share count to roughly 199.5 million, and was covered to about 70% including cornerstone commitments and underwriting guarantees. Management earmarked the proceeds to strengthen the balance sheet, fund a randomised Phase 2 study of around 90 patients, and support a series of investigator-initiated trials.
Comparison with earlier periods
The trajectory over the past year has been one of steady clinical de-risking against a backdrop of financial strain. In November 2025 Faron reported completion of the BEXMAB Phase 2 stage and alignment with the US Food and Drug Administration on advancing to a registrational trial. The June 2026 EHA data matured the response picture, and the July survival readout added the first OS dimension.
Set against 2025, when the central questions were whether responses would deepen and whether the company could fund the next study, the position in mid-2026 is materially clearer on both counts, even if the survival dataset remains early and small.
Strategy and growth drivers
Faron's strategy hinges on converting BEXMAB's Phase 1/2 signals into a registrational programme. Following a positive end-of-Phase 2 meeting disclosed in August 2025, the FDA endorsed a frontline development strategy and an accelerated-approval pathway. The planned registrational study opens with a dose-optimisation run-in comparing 1 mg/kg and 3 mg/kg bexmarilimab regimens against placebo, each with azacitidine, before transitioning into the registrational phase.
Co-primary endpoints are CR plus CR-equivalent under IWG 2023 criteria and overall survival, with composite complete remission as a key secondary measure. Chief Executive Dr Juho Jalkanen has said the company is 'only one study away' from a potential approval, a framing that captures both the opportunity and the concentration of risk in a single asset.
Industry and competitive context
HR-MDS remains an area of high unmet need. Azacitidine is the backbone of frontline care, but durable remissions are uncommon and TP53-mutated disease responds especially poorly. Several larger developers have pursued azacitidine combinations in MDS with mixed regulatory results, which sharpens the scrutiny any new entrant faces.
Faron's differentiated macrophage-reprogramming mechanism gives it a distinct scientific angle, but as a small-cap developer it competes for investigator attention, trial sites and capital against far better-resourced rivals.
Key risks
The central risks are familiar for single-asset biotech. The survival data derive from 21 patients in an open-label study without a randomised comparator, so the signal could soften as follow-up matures or fail to replicate in a controlled setting. Accelerated-approval pathways can shift, and a run-in dose-optimisation stage adds execution and timing risk.
Financially, the rights issue bought time rather than permanence: a pivotal trial is capital-intensive, and further dilution or partnering may be required. The enlarged share count already dilutes existing holders, and reliance on one indication leaves little margin for a clinical setback.
Milestones to monitor
Near-term catalysts include the presentation of a fuller BEXMAB dataset at a scientific meeting later in 2026, continued survival follow-up in the existing cohort, and progress on the randomised BEXERA study that the rights-issue proceeds are intended to fund. Confirmation of registrational trial timing, patient numbers and any regulatory designations would further clarify the path ahead.
Conclusion
Faron enters the second half of 2026 in a stronger clinical and financial position than it held a year earlier, with a maturing efficacy profile, an early but genuinely encouraging survival signal, and a funded route towards a registrational study. The headline's characterisation of an 'encouraging survival signal' is consistent with the company's own disclosures.
Balanced against that is the reality of a small, uncontrolled dataset, a capital-hungry pivotal programme and the fragility that comes with betting the business on one molecule. The coming data updates and trial-design confirmations should tell investors whether the early promise can withstand the rigour of a registrational setting.






Please wait processing your request...